Viral Conjunctivitis - Pipeline Review, H1 2017

Date: March 31, 2017
Pages: 43
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until September 1, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: V5BC2C93C86EN
Leaflet:

Download PDF Leaflet

Viral Conjunctivitis - Pipeline Review, H1 2017

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Viral Conjunctivitis – Pipeline Review, H1 2017, provides an overview of the Viral Conjunctivitis (Ophthalmology) pipeline landscape.

Viral conjunctivitis, or pinkeye, is a common, self-limiting condition that is typically caused by adenovirus. Viral conjunctivitis is highly contagious, usually for 10-12 days from onset as long as the eyes are red. Symptoms include itchy eyes, tearing, redness, discharge and light sensitivity (with corneal involvement). Treatment includes lubricants, vasoconstrictors and antihistamines.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Viral Conjunctivitis – Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Viral Conjunctivitis (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Viral Conjunctivitis (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Viral Conjunctivitis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 1 and 5 respectively.

Viral Conjunctivitis (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Viral Conjunctivitis (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Viral Conjunctivitis (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Viral Conjunctivitis (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Viral Conjunctivitis (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Viral Conjunctivitis (Ophthalmology)
REASONS TO BUY
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Viral Conjunctivitis (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Viral Conjunctivitis (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Viral Conjunctivitis – Overview
Viral Conjunctivitis – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Viral Conjunctivitis – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Viral Conjunctivitis – Companies Involved in Therapeutics Development
Adenovir Pharma AB
Marinomed Biotechnologie GmbH
NanoViricides Inc
Panoptes Pharma GesmbH
Shire Plc
Starpharma Holdings Ltd
Viral Conjunctivitis – Drug Profiles
APD-209 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APD-514 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
astodrimer – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EKCCide-I – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
iota-carrageenan – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OKG-0301 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PP-001 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SHP-640 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Viral Conjunctivitis – Dormant Projects
Viral Conjunctivitis – Discontinued Products
Viral Conjunctivitis – Product Development Milestones
Featured News & Press Releases
May 13, 2013: Starpharma's Dendrimer SPL7013 Demonstrates Potential As Viral Conjunctivitis Treatment
Oct 11, 2012: Adenovir Pharma Announces Completion Of Phase I Study Of APD -209 To Treat Epidemic Keratoconjunctivitis
Aug 22, 2011: Researchers Discover New Drug To Treat Epidemic Keratoconjuntivitis
May 05, 2010: Foresight Biotherapeutics, Inc 's Drug FST-100 Reduces Infectious Adenoviral Titers And Improves Clinical Signs in Conjunctivitis Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Viral Conjunctivitis, H1 2017
Number of Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Viral Conjunctivitis – Pipeline by Adenovir Pharma AB, H1 2017
Viral Conjunctivitis – Pipeline by Marinomed Biotechnologie GmbH, H1 2017
Viral Conjunctivitis – Pipeline by NanoViricides Inc, H1 2017
Viral Conjunctivitis – Pipeline by Panoptes Pharma GesmbH, H1 2017
Viral Conjunctivitis – Pipeline by Shire Plc, H1 2017
Viral Conjunctivitis – Pipeline by Starpharma Holdings Ltd, H1 2017
Viral Conjunctivitis – Dormant Projects, H1 2017
Viral Conjunctivitis – Discontinued Products, H1 2017

LIST OF FIGURES

Number of Products under Development for Viral Conjunctivitis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Molecule Types, H1 2017
Number of Products by Stage and Molecule Types, H1 2017

COMPANIES MENTIONED

Adenovir Pharma AB
Marinomed Biotechnologie GmbH
NanoViricides Inc
Panoptes Pharma GesmbH
Shire Plc
Starpharma Holdings Ltd
Skip to top


Ask Your Question

Viral Conjunctivitis - Pipeline Review, H1 2017
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: